ABBV vs CRM: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Salesforce, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-22.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Salesforce, Inc. · Technology
$236.42
+11.6% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
CRM has more upside to fair value
(+11.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
CRM |
| Current Price |
$261.70 |
$236.42 |
| Fair Value Estimate |
$259.04 |
$263.88 |
| Upside to Fair Value |
-1.0%
|
+11.6%
|
| Market Cap |
$462.4B |
$193.6B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
14.4x
|
| Price / Sales |
7.2x
|
4.4x
|
| Price / FCF |
23.6x
|
12.8x
|
| Revenue Growth YoY |
+10.2%
|
+10.8%
|
| Gross Margin |
71.5%
|
77.3%
|
| Operating Margin |
29.3%
|
21.4%
|
| Return on Equity |
-136.5%
|
20.2%
|
| Dividend Yield |
2.61% |
0.73% |
| FCF Yield |
4.25%
|
7.82%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Salesforce is the leading enterprise customer relationship management platform, spanning Sales, Service, Platform, Marketing, Commerce, Tableau, MuleSoft, and Slack under the Customer 360 umbrella, with 83,334 employees and a business that converts $53.65 of revenue per share into $18.48 of free cash flow per share. Business quality is high: TTM gross margin of 77.3%, TTM operating margin of 21.4…
Accumulation Zones
| Metric |
ABBV |
CRM |
| Zone Low |
$194.28 |
$197.91 |
| Zone High |
$220.18 |
$224.30 |
| In Buy Zone? |
No
|
No
|